logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Medivation Technologies, Inc.


USPTO Granted Patents = 63

% Expired Patents = 74.6



Forward Citations = 723

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Sarvajit Chakravarty (54 out of 87 patents)

silverMedal Rajendra Parasmal Jain (45 out of 48 patents)

bronzeMedal Andrew Asher Protter (26 out of 35 patents)

4.  David T Hung (19 out of 42 patents)

5.  Roopa Rai (8 out of 22 patents)

6.  Sundeep Dugar (8 out of 80 patents)

7.  Bing Wang (7 out of 64 patents)

8.  Barry Patrick Hart (7 out of 10 patents)

9.  Michael J Green (7 out of 61 patents)

10.  Daniel T Chu (7 out of 98 patents)

11.  Son Minh Pham (6 out of 26 patents)

12.  Brahmam Pujala (6 out of 22 patents)

13.  Bharat Uttam Shinde (5 out of 5 patents)

14.  Anjan Kumar Nayak (4 out of 11 patents)

15.  Sreekanth A Ramachandran (4 out of 8 patents)


Core Competencies:
Heterocyclic Compounds
Dihydropyridophthalazinone
Poly(ADP-Ribose)Polymerase
Diabetes Treatments
Hypertension Treatments
Fused Pyrimidine
Pyrido Indoles
Bridged Compounds
Tetracyclic Compounds
Azepino Indoles
Crystalline Compounds
Phenylcarbamoyl Compounds

63 patents:

1. 11702401 - Compounds and methods of use (2023-07-18),
2. 11364241 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2022-06-21),
3. 11053216 - Compounds and methods of use (2021-07-06),
4. 10780088 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2020-09-22),
5. 10543209 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2020-01-28),
6. 10501436 - Compounds and methods of use (2019-12-10),
7. 10493078 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency (2019-12-03),
8. 10189837 - Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt (2019-01-29),
9. 10189826 - Heterocyclic compounds and methods of use (2019-01-29),
10. 10183015 - Heterocyclic compounds and methods of use (2019-01-22),
11. 10030004 - Compounds and methods of use (2018-07-24),
12. 9926303 - Processes of synthesizing dihydropyridophthalazinone derivatives (2018-03-27),
13. 9820985 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2017-11-21),
14. 9670172 - Heterocyclic compounds and methods of use (2017-06-06),
15. 9580425 - Pyrido[3,4-b] indoles and methods of use (2017-02-28),
Medivation Technologies, Inc., based in San Francisco, CA, specializes in the development of innovative therapeutic solutions focusing on heterocyclic compounds. The company is engaged in advanced research in areas such as dihydropyridophthalazinone and poly(ADP-ribose) polymerase, targeting treatments for diabetes and hypertension. With a strong emphasis on fused pyrimidine, pyrido indoles, and bridged compounds, Medivation is committed to addressing significant health challenges through its cutting-edge technology and research initiatives.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Medivation Technologies, Inc.
63 Patents

#80 in San Francisco, CA

#1,343 in California

#5,753 in US

#11,611 in the World

San Francisco, CA (US)
San Francisco, CA, United States of America

Medivation Technologies, Inc.

Forward Citations = 723

40 inventors:

goldMedal Sarvajit Chakravarty (54 out of 87 patents)

silverMedal Rajendra Parasmal Jain (45 out of 48 patents)

bronzeMedal Andrew Asher Protter (26 out of 35 patents)

4.  David T Hung (19 out of 42 patents)

5.  Roopa Rai (8 out of 22 patents)

Please report any incorrect information to [email protected]
Loading…